1. Home
  2. REGN
  3. REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on July 2, 2025

Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices
REGN

Simply Wall St.

2 days ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Exits Multiple Russell Growth Indices

Former 23andMe CEO regains company control as $305m sale to nonprofit approved
REGN

Medical Device Network

2 days ago

Former 23andMe CEO regains company control as $305m sale to nonprofit approved

Circle initiated, Disney upgraded: Wall Street's top analyst calls
REGN

The Fly

2 days ago

Circle initiated, Disney upgraded: Wall Street's top analyst calls

REGN

MT Newswires

2 days ago

Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy

REGN

Argus Research

2 days ago

Analyst Report: Regeneron Phars, Inc

REGN

Argus Research

2 days ago

Market Digest: REGN

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
REGN

GlobeNewswire

6 days ago

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care
REGN

Insider Monkey

7 days ago

Regeneron Launches $200 Million Donation Matching Program to Support Vision Care

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
REGN

Zacks

7 days ago

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?
REGN

Zacks

8 days ago

Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip?

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
REGN

GlobeNewswire

8 days ago

Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization

UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).
REGN

Insider Monkey

9 days ago

UBS Lowers Price Target On Regeneron Pharmaceuticals, Inc. (REGN).

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call
REGN

StockStory

9 days ago

The Top 5 Analyst Questions From Regeneron’s Q1 Earnings Call

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks
REGN

StockStory

9 days ago

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week
REGN

The Wall Street Journal

12 days ago

The Score: 23andMe, U.S. Steel, Accenture and More Stocks That Defined the Week

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
REGN

Reuters

12 days ago

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M
REGN

Benzinga

12 days ago

From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe for $305M

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
REGN

Zacks

12 days ago

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

REGN

MT Newswires

12 days ago

Sector Update: Health Care

REGN

MT Newswires

12 days ago

Regeneron, Sanofi Say US FDA Approves Dupixent for Rare Skin Condition Disease

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
REGN

GlobeNewswire

12 days ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Shareholders Approve Bylaw Amendments at Regeneron Pharmaceuticals (NasdaqGS:REGN) Annual Meeting
REGN

Simply Wall St.

13 days ago

Shareholders Approve Bylaw Amendments at Regeneron Pharmaceuticals (NasdaqGS:REGN) Annual Meeting

Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold
REGN

Insider Monkey

13 days ago

Regeneron Pharmaceuticals, Inc. (REGN) Growth Story Shifts as Wells Fargo Maintains Hold

Celltrion opens new UK headquarters in Uxbridge, UK
REGN

Business Wire

13 days ago

Celltrion opens new UK headquarters in Uxbridge, UK

REGN

MT Newswires

15 days ago

Sector Update: Health Care Stocks Retreat Late Afternoon

REGN

MT Newswires

15 days ago

Update: Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

Anne Wojcicki wins bid to buy back 23andMe for $305M
REGN

MedTech Dive

15 days ago

Anne Wojcicki wins bid to buy back 23andMe for $305M

REGN

MT Newswires

15 days ago

Market Chatter: Regeneron Pharmaceuticals Opts Out From Raising Offer for 23andMe

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction
REGN

BioPharma Dive

15 days ago

FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction

Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data
REGN

Yahoo Finance

15 days ago

Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data

Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data
REGN

Yahoo Finance

15 days ago

Anne Wojcicki's bid to buy back 23andMe may not end a legal fight over DNA customer data

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
REGN

Reuters

16 days ago

Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
REGN

Pharmaceutical Technology

16 days ago

EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM

REGN

MT Newswires

16 days ago

Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million

REGN

MT Newswires

16 days ago

Sanofi, Regeneron Say Dupixent Outperforms Xolair in Phase 4 Respiratory Trial

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
REGN

GlobeNewswire

17 days ago

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
REGN

Motley Fool

17 days ago

These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025

Anne Wojcicki Wins Bidding for 23andMe
REGN

The Wall Street Journal

19 days ago

Anne Wojcicki Wins Bidding for 23andMe

23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
REGN

Reuters

19 days ago

23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
REGN

GlobeNewswire

19 days ago

23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
REGN

Motley Fool

19 days ago

These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025

Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch
REGN

Yahoo Finance Video

19 days ago

Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher
REGN

Fortune

20 days ago

Dozens of states sue to block the sale of 23andMe’s genetic data after its former CEO pushes the purchase price $50 million higher

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
REGN

Motley Fool

20 days ago

Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
REGN

Insider Monkey

20 days ago

JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target

23andMe says 15% of customers asked to delete their genetic data since bankruptcy
REGN

TechCrunch

21 days ago

23andMe says 15% of customers asked to delete their genetic data since bankruptcy

Stock Market News for Jun 10, 2025
REGN

Zacks

22 days ago

Stock Market News for Jun 10, 2025

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
REGN

Benzinga

23 days ago

Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season

Regeneron and Sanofi’s dupilumab shows promise in AD trial
REGN

Clinical Trials Arena

23 days ago

Regeneron and Sanofi’s dupilumab shows promise in AD trial

As tech leads, which stocks have outperformed since April 8 rout?
REGN

Yahoo Finance Video

23 days ago

As tech leads, which stocks have outperformed since April 8 rout?

REGN

MT Newswires

23 days ago

JPMorgan Adjusts PT on Regeneron Pharmaceuticals to $800 From $950, Maintains Overweight Rating

REGN

MT Newswires

23 days ago

Regeneron, Sanofi Say Atopic Dermatitis Trial Shows Improvement in Disease Severity

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
REGN

GlobeNewswire

25 days ago

Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
REGN

Insider Monkey

a month ago

Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory

Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?
REGN

Zacks

a month ago

Can New Cancer Drug Emrelis Drive AbbVie's Oncology Franchise?

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial
REGN

Barrons.com

a month ago

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial

The New Twist In Regeneron's 23andMe Bankruptcy Buyout
REGN

Investor's Business Daily

a month ago

The New Twist In Regeneron's 23andMe Bankruptcy Buyout

REGN

MT Newswires

a month ago

UBS Adjusts Regeneron Pharmaceuticals Price Target to $560 From $633, Maintains Neutral Rating

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?
REGN

Zacks

a month ago

REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher
REGN

The Wall Street Journal

a month ago

23andMe’s Former CEO Pushes Purchase Price Nearly $50 Million Higher

23andMe seeks new bids after $305 million offer from its co-founder
REGN

Reuters

a month ago

23andMe seeks new bids after $305 million offer from its co-founder

REGN

MT Newswires

a month ago

Wolfe Research Adjusts Price Target on Regeneron Pharmaceuticals to $800 From $925

Regeneron makes obesity push; Atai, Alto ink brain drug deals
REGN

BioPharma Dive

a month ago

Regeneron makes obesity push; Atai, Alto ink brain drug deals

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights
REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights

Regeneron price target lowered to $600 from $800 at BMO Capital
REGN

TipRanks

a month ago

Regeneron price target lowered to $600 from $800 at BMO Capital

Regeneron to acquire rights for Hansoh’s HS-20094 therapy
REGN

Pharmaceutical Technology

a month ago

Regeneron to acquire rights for Hansoh’s HS-20094 therapy

REGN

MT Newswires

a month ago

Regeneron Says Phase 2 Obesity Study Interim Results Show Semaglutide Combination Preserves Lean Mass

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
REGN

Benzinga

a month ago

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

REGN

MT Newswires

a month ago

Regeneron Pharmaceuticals Partners With Hansoh Pharma to Develop GLP-1 Drug

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
REGN

Pharmaceutical Technology

a month ago

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles
REGN

Clinical Trials Arena

a month ago

ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip
REGN

Motley Fool

a month ago

The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip

Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.
REGN

Barrons.com

a month ago

Kymera Stock Jumps 41%. New Dermatitis Pill Could Challenge Regeneron Blockbuster.

REGN

MT Newswires

a month ago

Regeneron Says Libtayo Shows Strong Results in Adjuvant Skin Cancer Trial

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
REGN

GlobeNewswire

a month ago

Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
REGN

GlobeNewswire

a month ago

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass

REGN

Pharmaceutical Technology

a month ago

Sanofi and Regeneron report results from two Phase III trials of COPD treatment

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial
REGN

Simply Wall St.

a month ago

Regeneron Pharmaceuticals (NasdaqGS:REGN) Reports 27% Reduction In COPD Exacerbations In Phase 3 Trial

This week in Trumponomics: Too bad TACO isn’t true
REGN

Yahoo Finance

a month ago

This week in Trumponomics: Too bad TACO isn’t true

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
REGN

Yahoo Finance Video

a month ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says
REGN

Reuters

a month ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
REGN

USA TODAY

a month ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Saturday Sessions: OK Go performs "Love"
REGN

CBS News Videos

a month ago

Saturday Sessions: OK Go performs "Love"

Behind the scenes of an OK Go music video
REGN

CBS News Videos

a month ago

Behind the scenes of an OK Go music video

Some Investors May Be Worried About Marine Products' (NYSE:MPX) Returns On Capital
REGN

Simply Wall St.

a month ago

Some Investors May Be Worried About Marine Products' (NYSE:MPX) Returns On Capital

Dow Jones Futures: Stocks At Key Levels Amid Trump Tariff News; Palantir Breaks Out As Tesla, Nvidia Fall Back
REGN

Investor's Business Daily

a month ago

Dow Jones Futures: Stocks At Key Levels Amid Trump Tariff News; Palantir Breaks Out As Tesla, Nvidia Fall Back

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
REGN

GlobeNewswire

a month ago

Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing

REGN

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet
REGN

Investopedia

a month ago

S&P 500 Gains & Losses Today: Ulta Beauty Stock Soars; Regeneron Shares Plummet

Regeneron stock sinks over trial data for smoker's lungs drug
REGN

Yahoo Finance Video

a month ago

Regeneron stock sinks over trial data for smoker's lungs drug

REGN

MT Newswires

a month ago

Top Midday Decliners

REGN

MT Newswires

a month ago

Jefferies Lowers Regeneron Pharmaceuticals' Price Target to $804 From $914

REGN

MT Newswires

a month ago

RBC Capital Downgrades Regeneron Pharmaceuticals to Sector Perform From Outperform, Price Target is $662

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance
REGN

GuruFocus.com

a month ago

Nvidia (NVDA) Gets Wall Street Boost on Strong Q1 Results and Upbeat Guidance

Swiss officials halt further evacuations after glacier collapse
REGN

AFP

a month ago

Swiss officials halt further evacuations after glacier collapse

Family RV Association Announces Dates For Future National Rallies
REGN

PR Newswire

a month ago

Family RV Association Announces Dates For Future National Rallies

Semiconductor Gas Abatement Systems Market Poised to Reach USD 5.8 Billion by 2034 | Exactitude Consultancy
REGN

GlobeNewswire

a month ago

Semiconductor Gas Abatement Systems Market Poised to Reach USD 5.8 Billion by 2034 | Exactitude Consultancy

Government of Canada to build new research facility to improve transportation safety
REGN

CNW Group

a month ago

Government of Canada to build new research facility to improve transportation safety

GlobeMed Saudi ties up with Orient Insurance to offer healthcare services
REGN

Life Insurance International

a month ago

GlobeMed Saudi ties up with Orient Insurance to offer healthcare services

Share on Social Networks: